DFX Intelligence
Borrowers
150 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Health Care Equipment” (remove)
Start from
150 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| Healthco Investment LTD EUR Life sciences | unattributed | 1 | at least $26.6M | n/a | n/a | Sep 9, 2032 | Sep 30, 2025 |
| Centinel Spine, LLC Life sciences | Sponsor not establishedpossible: Birnam Wood Capital, LLC (a company of this name is on the sponsor's portfolio page) | 3 | at least $25.1M | 103c | n/a | Mar 31, 2030 | Mar 31, 2025 |
| MedMinder Systems, Inc Life sciences | unattributed | 1 | at least $25.0M | 106c | n/a | Aug 18, 2028 | Jun 30, 2026 |
| A•••••• T••••••••• I•• Life sciences | A•••••••• C•••••• P••••••• inferred | 6 | at least $22.9M | 59c | 0 pts | Dec 31, 2028 | Dec 31, 2021 |
| S••••• R••••••••• L•• Life sciences | unattributed | 2 | at least $21.9M | 72c | n/a | Dec 29, 2028 | Dec 31, 2022 |
| M•••••• D••••• I•• Life sciences | unattributed | 4 | at least $21.3M | 100c | 1 pts | Jul 11, 2029 | Sep 30, 2023 |
| C•••••• H•••••••• B•••• G••• Life sciences | unattributed | 1 | at least $21.1M | 105c | n/a | Jun 28, 2030 | Jun 30, 2023 |
| A•• O•• B•••• Life sciences | unattributed | 1 | at least $20.8M | 100c | n/a | May 16, 2031 | Jun 30, 2025 |
| N••••••••• I•• Life sciences | unattributed | 1 | at least $20.0M | 100c | n/a | May 27, 2030 | Jun 30, 2025 |
| F••••••••• N• Life sciences | unattributed | 1 | at least $20.0M | 100c | n/a | May 7, 2032 | Mar 31, 2025 |
| V••••••••• I•• Life sciences | unattributed | 3 | at least $19.8M | 99c | 0 pts | Sep 30, 2027 | Dec 31, 2022 |
| S••••• S•••••• H••••••• A••••••••• I•• Life sciences | unattributed | 2 | at least $19.8M | 101c | 0 pts | Mar 20, 2030 | Jun 30, 2024 |
| U••••••••• Life sciences | unattributed | 1 | at least $19.7M | 100c | n/a | May 24, 2029 | Dec 31, 2024 |
| L•• I••••••••• L•• Life sciences | unattributed | 2 | at least $19.4M | 102c | n/a | Nov 3, 2027 | Dec 31, 2024 |
| P•••••• D••••• C••• M••••••••• L•• Life sciences | unattributed | 1 | at least $18.1M | 100c | n/a | Aug 31, 2027 | Dec 31, 2022 |
| N•••• S••••••• I•• Life sciences | unattributed | 2 | at least $17.8M | 99c | 2 pts | Jan 7, 2031 | Mar 31, 2025 |
| M•• D••••• Life sciences | W•••••• P••••• L•• inferred | 3 | at least $17.3M | 101c | 0 pts | Feb 13, 2031 | Dec 31, 2023 |
| O••••• M•••••• Life sciences | unattributed | 1 | at least $17.1M | 104c | n/a | Jun 15, 2028 | Jun 30, 2024 |
| S••••• U• B•••• C••• Life sciences · grade B | unattributed | 1 | at least $15.5M | 105c | n/a | Jul 31, 2029 | Dec 31, 2022 |
| C•• T• M••••• S••• L•• Life sciences | unattributed | 1 | at least $15.0M | 100c | n/a | May 31, 2029 | Jun 30, 2023 |
| S••••• B•••• I• I••• I•••••• U••• D••••• Life sciences | unattributed | 1 | at least $14.4M | 100c | n/a | Feb 2, 2032 | Mar 31, 2025 |
| B••••••••• I•• Life sciences | unattributed | 1 | at least $13.8M | 101c | n/a | May 15, 2027 | Jun 30, 2026 |
| P••••••••• I••••••••• L• Life sciences | H•••••• I••••••••• M••••••••• L••••• inferred | 3 | at least $13.6M | 101c | n/a | Sep 30, 2027 | Dec 31, 2022 |
| H• P••••••••• L•• Life sciences | unattributed | 2 | at least $13.6M | 100c | 0 pts | Jan 29, 2031 | Mar 31, 2026 |
| H• I•••• M••••• S••• I•• Life sciences | unattributed | 1 | at least $13.4M | 100c | n/a | May 31, 2033 | Jun 30, 2026 |
| S••••••••• I••••••••• Life sciences | unattributed | 1 | at least $13.1M | 101c | n/a | Dec 31, 2029 | Dec 31, 2022 |
| C•••••• S••••••••• H•••••••• L•• Life sciences | unattributed | 1 | at least $12.4M | 100c | n/a | Jun 30, 2027 | Dec 31, 2022 |
| P•••••• T•••• T•••• M•••••• L•• Life sciences | unattributed | 2 | at least $12.2M | 99c | 0 pts | Jun 12, 2031 | Mar 31, 2026 |
| G••••• S•••• B••••• I•• Life sciences | unattributed | 7 | at least $12.1M | 100c | n/a | Apr 2, 2031 | Dec 31, 2021 |
| C• M•••••• B• I•• A••••••••• L•• Life sciences | unattributed | 2 | at least $11.9M | 100c | 0 pts | Nov 1, 2027 | Dec 31, 2025 |
| P••••••• O••••••• M•••• 2• L•• Life sciences | unattributed | 2 | at least $11.6M | 100c | 1 pts | Jul 17, 2028 | Dec 31, 2022 |
| I••••••••• I•• Life sciences | unattributed | 1 | at least $11.5M | 109c | n/a | Feb 5, 2030 | Jun 30, 2026 |
| H••••••• P••••••• M••••••••• L•• Life sciences | unattributed | 1 | at least $11.5M | 101c | n/a | May 31, 2027 | Dec 31, 2022 |
| M•••••• R••••• I•••••••• o• A•••••• Life sciences | Sponsor not establishedpossible: P•••••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 3 | at least $11.2M | 100c | 0 pts | Jul 31, 2030 | Mar 31, 2024 |
| U•••••• V••••• P••••••• Life sciences | Sponsor not establishedpossible: W••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $11.0M | 99c | n/a | Sep 30, 2027 | Dec 31, 2022 |
| G•••••••• M•••••• S•••••••• L•• Life sciences | unattributed | 1 | at least $9.6M | 58c | n/a | Jun 30, 2026 | Dec 31, 2022 |
| J•••••• P••••••• C••• C••• Life sciences | unattributed | 6 | at least $8.8M | 100c | n/a | Mar 1, 2028 | Feb 29, 2024 |
| C••••••••• H•••••• I•• Life sciences | unattributed | 4 | at least $8.7M | 101c | n/a | Mar 31, 2031 | Dec 31, 2021 |
| E•• O••• 1• L•• Life sciences | unattributed | 2 | at least $8.5M | 92c | n/a | Mar 26, 2031 | Sep 30, 2025 |
| S••••••• L•• Life sciences | unattributed | 2 | at least $8.5M | 98c | 1 pts | Jun 12, 2028 | Dec 31, 2022 |
| A•••••• H••••• Life sciences | Sponsor not establishedpossible: L•••••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $8.3M | 101c | n/a | Feb 28, 2029 | Mar 31, 2024 |
| E•••••• C••• Life sciences | unattributed | 6 | at least $8.1M | 80c | n/a | Mar 30, 2029 | Sep 30, 2022 |
| A•• H••••••••• I•• Life sciences | unattributed | 1 | at least $8.0M | 96c | n/a | Mar 8, 2028 | Dec 31, 2023 |
| L•• C••••••••• S••••••• L•• Life sciences | unattributed | 2 | at least $7.3M | n/a | n/a | May 1, 2031 | Jun 30, 2025 |
| L••••••••• L•• S••••••• Life sciences | unattributed | 1 | at least $6.7M | 100c | n/a | Oct 31, 2027 | Mar 31, 2023 |
| H••••••• I••••••••• L•• G•• Life sciences | unattributed | 1 | at least $6.6M | n/a | n/a | Sep 9, 2032 | Sep 30, 2025 |
| R•• B••••••••• H•••••• L•• Life sciences | unattributed | 1 | at least $6.6M | 101c | n/a | Dec 31, 2030 | Dec 31, 2024 |
| C• A••••• M••••••••• L•• Life sciences | unattributed | 1 | at least $6.6M | 101c | n/a | Aug 31, 2027 | Mar 31, 2023 |
| N•••••• C••• P••••••• H•••••••• I•• Life sciences | unattributed | 1 | at least $6.5M | 101c | n/a | Oct 1, 2030 | Dec 31, 2024 |
| P••••••••• I•• Life sciences | unattributed | 1 | at least $6.5M | 101c | n/a | Dec 30, 2030 | Dec 31, 2024 |
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.